# EDGAR Filing Document

**Accession Number:** 0001596812
**File Stem:** 0001213900-26-027685
**Filing Date:** 2026-3
**Character Count:** 20062
**Document Hash:** 789e1b1560610c6d2f5d4168fd89104a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-027685.hdr.sgml**: 20260313

**ACCESSION NUMBER**: 0001213900-26-027685

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 16

**FILED AS OF DATE**: 20260313

**DATE AS OF CHANGE**: 20260313

**EFFECTIVENESS DATE**: 20260313

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Enlivex Ltd.
- **CENTRAL INDEX KEY:** 0001596812
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294284
- **FILM NUMBER:** 26752696

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 37 DEREH MENACHEM BEGIN ST.
- **STREET 2:** 15TH FLOOR
- **CITY:** TEL AVIV
- **PROVINCE COUNTRY:** L3
- **BUSINESS PHONE:** 972 (0) 3 7326616

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 37 DEREH MENACHEM BEGIN ST.
- **STREET 2:** 15TH FLOOR
- **CITY:** TEL AVIV
- **PROVINCE COUNTRY:** L3

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Enlivex Therapeutics Ltd.
- **DATE OF NAME CHANGE:** 20190326

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Bioblast Pharma Ltd.
- **DATE OF NAME CHANGE:** 20160919

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BIO BLAST PHARMA LTD.
- **DATE OF NAME CHANGE:** 20140113

**As filed with the Securities and Exchange Commission on March 13, 2026**

**Registration No. 333-** 

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION**<br> **Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

**Enlivex Ltd.** ****<br> (Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Israel** | **Not Applicable** |
| (State or other jurisdiction of <br> incorporation or organization) | (I.R.S. Employer <br> Identification No.) |

---

---

| | |
|:---|:---|
| **14 Einstein Street <br> Nes Ziona, Israel** | **7403618** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

**Enlivex Therapeutics Ltd.**

(Former name, former address, and former fiscal year, if changed since last report)

**Enlivex Therapeutics Ltd. Global Share Incentive Plan (2019)**

(Full title of the plan)

**Cogency Global Inc.**

**122 East 42nd Street, 18th Floor**

**New York, New York 10168**

(Name and address of agent for service)

**(212) 947-7200**<br> (Telephone number, including area code, of agent for service)

**Copy to:**

---

| | |
|:---|:---|
| **Drew M. Altman, Esq.** | **Sharon Rosen, Adv.** |
| **Win Rutherfurd, Esq.** | **FISCHER (FBC & Co.)** |
| **Greenberg Traurig, P.A.** | **146 Menachem Begin Street Tel Aviv** |
| **333 S.E. 2nd Avenue, Suite 4400** | **6492103, Israel** |
| **Miami, Florida 33131** | **+972 -3-6944111** |
| **(305) 579-0500** |  |

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act:

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☐ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**PART I<br>INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS**

This Registration Statement on Form S-8 is being filed by Enlivex Ltd., a company organized under the laws of the State of Israel (the "<u>Registrant</u>"), for the purpose of registering a total of 22,700,851 additional ordinary shares, par value NIS 0.40 per share ("<u>Ordinary Shares</u>"), issuable under the Enlivex Therapeutics Ltd. Global Share Incentive Plan (2019) (as amended, the "<u>Plan</u>").

Pursuant to Instruction E of Form S-8, the contents of the Registrant's prior registration statement on Form S-8 registering Ordinary Shares under the Plan (File No. 333-256799) (the "<u>Prior Registration Statement</u>") are hereby incorporated by reference herein, and the information required by Form S-8 is omitted, except that the provisions contained in Part II of the Prior Registration Statement are modified as set forth in this Registration Statement.

**PART II<br>INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. <u>Incorporation of Documents by Reference</u>.**

The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed with the Securities and Exchange Commission (the "<u>Commission</u>"), other than, in each case, documents or information deemed to have been furnished and not filed in accordance with Commission rules:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The
 Registrant's Annual Report on [Form 20-F](https://www.sec.gov/Archives/edgar/data/1596812/000121390025037657/ea0239161-20f_enlivex.htm) for the year ended December 31, 2024, filed
 with the Commission on April 30, 2025;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The
 Registrant's Current Reports on Form 6-K filed with the Commission on [May 30, 2025](https://www.sec.gov/Archives/edgar/data/1596812/000121390025049492/ea0243609-6k_enlivex.htm) , [August 18, 2025](https://www.sec.gov/Archives/edgar/data/1596812/000121390025077714/ea0253587-6k_enlivex.htm) , [August 18, 2025](https://www.sec.gov/Archives/edgar/data/1596812/000121390025077718/ea0253652-6k_enlivex.htm) (two
 reports), [August 29, 2025](https://www.sec.gov/Archives/edgar/data/1596812/000121390025082585/ea0254617-6k_enlivex.htm) , [November 14, 2025](https://www.sec.gov/Archives/edgar/data/1596812/000121390025110920/ea0265573-6k_enlivex.htm) , [November 18, 2025](https://www.sec.gov/Archives/edgar/data/1596812/000121390025111782/ea0266091-6k_enlivex.htm) , [November 24, 2025](https://www.sec.gov/Archives/edgar/data/1596812/000121390025113831/ea0266869-6k_enlivex.htm) , [November 24, 2025](https://www.sec.gov/Archives/edgar/data/1596812/000121390025113881/ea0266870-6k_enlivex.htm) (two reports), [November 26, 2025](https://www.sec.gov/Archives/edgar/data/1596812/000121390025115075/ea0267296-6k_enlivex.htm) , [December 18, 2025](https://www.sec.gov/Archives/edgar/data/1596812/000121390025123303/ea0270119-6k_enlivex.htm) , [January 23, 2026](https://www.sec.gov/Archives/edgar/data/1596812/000121390026006926/ea0273631-6k_enlivex.htm) , [February 5, 2026](https://www.sec.gov/Archives/edgar/data/1596812/000121390026012548/ea0275705-6k_enlivex.htm) and [February 23, 2026](https://www.sec.gov/Archives/edgar/data/1596812/000121390026019019/ea0277907-6k_enlivex.htm) ; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The
 Registrant's Registration Statement on [Form 8-A](https://www.sec.gov/Archives/edgar/data/1596812/000114420414045171/v384900_8a12b.htm) (File No. 001-36578), filed with the
 Commission on July 28, 2014, in which there is described the terms, rights and provisions
 applicable to our ordinary shares, including any amendment or report filed for the purpose
 of updating such description, including the description of ordinary shares filed as [Exhibit 2.1](https://www.sec.gov/Archives/edgar/data/1596812/000121390024037878/ea020457001ex2-1_enlivex.htm) to our Annual Report on [Form 20-F](https://www.sec.gov/ix?doc=/Archives/edgar/data/1596812/000121390024037878/ea0204570-20f_enlivex.htm) for the year ended December 31, 2023, filed with the
 Commission on April 30, 2024.

Additionally, all documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (not including any information that is identified as "furnished" rather than filed, which information is not incorporated by reference herein), prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated herein by reference and to be a part of the Registration Statement from the date of filing of such documents. The Registrant may also incorporate any Form 6-K subsequently filed or furnished by it to the Commission prior to the filing of any such post-effective amendment, by identifying in such Form 6-K that it is being incorporated by reference herein, and any Forms 6-K so identified shall be deemed to be incorporated herein by reference and to be a part of the Registration Statement from the date of filing or furnishing of such Form 6-K. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of the Registration Statement to the extent that a statement contained herein, or in any other subsequently filed document that also is deemed to be incorporated by reference herein, modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of the Registration Statement.

**Item 8. <u>Exhibits</u>.**

The following are the exhibits required by Item 601 of Regulation S-K:

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **Description** |
| 1.1 | [Amended Articles of Association of the Enlivex Ltd. (filed as Exhibit 99.1 to the Registrant's Report on Form 6-K, filed with the SEC on February 5, 2026, and incorporated by reference herein).](https://www.sec.gov/Archives/edgar/data/1596812/000121390026012548/ea027570501ex99-1_enlivex.htm) |
| 5.1\* | [Opinion of Fischer (FBC & CO.).](ea028137201ex5-1.htm) |
| 23.1\* | [Consent of Yarel + Partners, independent registered certified public accounting firm.](ea028137201ex23-1.htm) |
| 23.3\* | [Consent of Fischer (FBC & CO.) (included in Exhibit 5.1).](ea028137201ex5-1.htm) |
| 24.1\* | [Power of Attorney (included on signature page hereto).](#poa_001) |
| 99.1 | [Enlivex Therapeutics Ltd. Global Share Incentive Plan (2019) (filed as Exhibit 4.3 to the Registrant's Annual Report on Form 20-F, filed with the SEC on April 30, 2020 and incorporated by reference herein).](https://www.sec.gov/Archives/edgar/data/1596812/000121390020010632/f20f2019ex4-3_enlivex.htm)  |
| 107.1\* | [Filing Fee Table.](ea028137201ex-fee.htm) |

---

\* Filed herewith.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Nes-Ziona, State of Israel, on March 13, 2026.

---

| | | |
|:---|:---|:---|
| ENLIVEX LTD. | ENLIVEX LTD. | ENLIVEX LTD. |
| By: | /s/ Oren Hershkovitz | /s/ Oren Hershkovitz |
|  | Name: | Oren Hershkovitz |
|  | Title: | Chief Executive Officer |

---

**POWER OF ATTORNEY**

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Shai Novik and Shachar Shlosberger, and each of them any of whom may act without joinder of the other, with full power to act as such person's true and lawful attorneys-in-fact and agent, with full power of substitution and resubstitution, for such person and in such person's name, place and stead, in any and all capacities, to sign this Registration Statement, and any and all amendments thereto (including post-effective amendments), and to file the same, with exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agent or his substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

---

| | | |
|:---|:---|:---|
| **Name** | **Title** | **Date** |
| /s/ Oren Hershkovitz | Chief Executive Officer | March 13, 2026 |
| Oren Hershkovitz | (Principal Executive Officer) |  |
| /s/ Shachar Shlosberger | Chief Financial Officer | March 13, 2026 |
| Shachar Shlosberger | (Principal Financial and Accounting Officer) |  |
| /s/ Shai Novik | Chairman of the Board of Directors | March 13, 2026 |
| Shai Novik |  |  |
| /s/ Abraham Havron | Director | March 13, 2026 |
| Abraham Havron |  |  |
| /s/ Gili Hart, Ph.D. | Director | March 13, 2026 |
| Gili Hart, Ph.D. |  |  |
| /s/ Roger Pomerantz | Director | March 13, 2026 |
| Roger Pomerantz, M.D. |  |  |
|  | Director |  |
| Matteo Renzi |  |  |

---

**Signature of Authorized U.S. Representative of Registrant**

Pursuant to the requirements of the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Enlivex Ltd., has signed this Registration Statement on March 13, 2026.

---

| | |
|:---|:---|
| By: | /s/ Colleen De Vries |
| Name: | Colleen De Vries |
| Title: | Sr. Vice President on behalf of Cogency Global Inc. |

---

## Exhibit 5.1

**Exhibit 5.1**

![](ea028137201_ex5-1img1.jpg)

Tel. 972-3-69441111 <br> Fax. 972-3-6091116 <br> <u>fbc@fbclawyers.com</u>

March 13, 2026

Enlivex Ltd.

14 Einstein Street

Ness Ziona, Israel 7403618

Ladies and Gentlemen:

We have acted as Israeli counsel to Enlivex Ltd., a company organized under the laws of the State of Israel (the "<u>Company</u>"), in connection with its filing of a registration statement on Form S-8 (the "<u>Registration Statement</u>") with the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), for the registration of an additional 22,700,851 ordinary shares, par value NIS 0.40 per share ("<u>Ordinary Shares</u>"), of the Company (the "<u>Shares</u>"), issuable under the Enlivex Therapeutics Ltd. Global Share Incentive Plan (2019) (the "<u>Plan</u>").

In rendering the opinion expressed herein, we have examined the originals or copies certified or otherwise identified to our satisfaction of (i) the Registration Statement to which this opinion letter is attached as an exhibit; (ii) the articles of association of the Company, as currently in effect (the "<u>Articles</u>"); (iii) the Plan; (iv) resolutions of the board of directors of the Company (the "<u>Board</u>"), and (v) such other corporate records or other documents and such certificates or comparable documents of public officials and of officers and representatives of the Company as we have deemed relevant and necessary as a basis for this opinion. We have also made inquiries of such officers and representatives as we have deemed relevant and necessary as a basis for this opinion.

In such examination, we have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as reproduced or certified copies, and the authenticity of the originals of such latter documents. We have assumed the same to have been properly given and to be accurate. We have also assumed the truth of all facts communicated to us by the Company and that all consents and minutes of meetings of the Board that have been provided to us are true and accurate and have been properly prepared in accordance with the Articles and all applicable laws. In addition, we have assumed that the Company will receive full consideration for the Shares (which may consist, in part or in full, of services performed for the Company). We have further assumed that the consideration for the issuance and sale of the Shares shall be in an amount that is not less than the nominal (par) value of the Ordinary Shares.

Members of our firm are admitted to the Bar in the State of Israel, and we do not express any opinion as to the laws of any other jurisdiction. This opinion is limited to the matters stated herein and no opinion is implied or may be inferred beyond the matters expressly stated.

Based upon and subject to the foregoing and to the assumptions and qualifications set forth herein, we are of the opinion that the Shares, when paid for and issued in accordance with the terms of the Plan and the grants thereunder, will be validly issued, fully paid and non-assessable.

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement. In giving this consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations promulgated thereunder.

This opinion letter is rendered as of the date hereof and we disclaim any obligation to advise you of facts, circumstances, events or developments that may be brought to our attention after the effective date of the Registration Statement that may alter, affect or modify the opinions expressed herein.

---

| |
|:---|
| Very truly yours, |
| /s/ FISCHER (FBC & Co.) |
| FISCHER (FBC & Co.) |

---

## Exhibit 23.1

**Exhibit 23.1**

![](ea028137201_ex23-1img1.jpg)

CONSENT OF INDEPENDENT ACCOUNTANTS

We consent to the incorporation by reference in the Registration Statement on Form S-8 of Enlivex Ltd. of our report dated March 31, 2025, with respect to the consolidated financial statements and the effectiveness of internal control over financial reporting of Enlivex Ltd., filed with the Securities and Exchange Commission on March 31, 2025.

---

| |
|:---|
| /s/ Yarel + Partners |
| Yarel + Partners |
| Tel- Aviv, Israel |
| March 13, 2026 |

---

## Ex-Filing

?xml version='1.0' encoding='ASCII'? Filing Fee Exhibit

**Ex-Filing Fees**

**CALCULATION OF FILING FEE TABLES**

**S-8**

**Enlivex Ltd.**

**Table 1: Newly Registered Securities**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Class Title** | **Notes** | **Fee Calculation<br> Rule** | **Amount Registered** | **Proposed Maximum Offering<br> Price Per Unit** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| Equity | Ordinary Shares, par value NIS 0.40 per share, to be issued under the Enlivex Therapeutics Ltd. Global Shares Incentive Plan (2019) | (1) | Other | 22700851 | $1.13 | $25651961.63 | 0.0001381 | $3542.54 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | $25651961.63 |  | 3542.54 |
| Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: |  |  |  |
| Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: |  |  | $3542.54 |

---

**__________________________________________ Offering Note(s)**

&nbsp;&nbsp;&nbsp;&nbsp;(1) Pursuant to Rule 416 of the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional ordinary shares, par value NIS 0.40 per share ("Ordinary Shares"), of Enlivex Ltd. (the "Registrant") that become issuable under the Enlivex Ltd. Global Shares Incentive Plan (2019) by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the receipt of consideration that results in an increase in the number of outstanding Ordinary Shares. Estimated solely for purposes of calculating the registration fee in accordance with Rules 457(c) and 457(h) of the Securities Act and based upon the average of the high and low sales prices of the Registrant's Ordinary Shares as reported on the Nasdaq Capital Market on March 11, 2026.